ERBB2 and breast carcinoma: Combining EB1089 with other therapies, including endocrine and anti-HER2 treatments, has shown promising outcomes in overcoming resistance and enhancing treatment efficacy in breast cancer, both in in vitro and in vivo studies [9,11,24,36,37].